scholarly journals PCN131 THE COST OF TREATING LUNG CANCER IN THE UNITED STATES: AN ANALYSIS OF THE MEDICAL EXPENDITURE PANEL SURVEY

2010 ◽  
Vol 13 (3) ◽  
pp. A48
Author(s):  
P Nadpara ◽  
C Tworek ◽  
S Madhavan
2010 ◽  
Vol 13 (2) ◽  
Author(s):  
John F Cogan ◽  
R. Glenn Hubbard ◽  
Daniel Kessler

In this paper, we use publicly available data from the Medical Expenditure Panel Survey - Insurance Component (MEPS-IC) to investigate the effect of Massachusetts' health reform plan on employer-sponsored insurance premiums. We tabulate premium growth for private-sector employers in Massachusetts and the United States as a whole for 2004 - 2008. We estimate the effect of the plan as the difference in premium growth between Massachusetts and the United States between 2006 and 2008—that is, before versus after the plan—over and above the difference in premium growth for 2004 to 2006. We find that health reform in Massachusetts increased single-coverage employer-sponsored insurance premiums by about 6 percent, or $262. Although our research design has important limitations, it does suggest that policy makers should be concerned about the consequences of health reform for the cost of private insurance.


2013 ◽  
Vol 8 (1) ◽  
pp. 82-90 ◽  
Author(s):  
Geraldine Pierre ◽  
Roland J. Thorpe ◽  
Gniesha Y. Dinwiddie ◽  
Darrell J. Gaskin

This article sought to determine whether racial disparities exist in psychotropic drug use and expenditures in a nationally representative sample of men in the United States. Data were extracted from the 2000-2009 Medical Expenditure Panel Survey, a longitudinal survey that covers the U.S. civilian noninstitutionalized population. Full-Year Consolidated, Medical Conditions, and Prescribed Medicines data files were merged across 10 years of data. The sample of interest was limited to adult males aged 18 to 64 years, who reported their race as White, Black, Hispanic, or Asian. This study employed a pooled cross-sectional design and a two-part probit generalized linear model for analyses. Minority men reported a lower probability of psychotropic drug use (Black = −4.3%, 95% confidence interval [CI] = [−5.5, −3.0]; Hispanic = −3.8%, 95% CI = [−5.1, −2.6]; Asian = −4.5%, 95% CI = [−6.2, −2.7]) compared with White men. After controlling for demographic, socioeconomic, and health status variables, there were no statistically significant race differences in drug expenditures. Consistent with previous literature, racial and ethnic disparities in the use of psychotropic drugs present problems of access to mental health care and services.


2011 ◽  
Vol 127 (2) ◽  
pp. 363-369.e3 ◽  
Author(s):  
Patrick W. Sullivan ◽  
Vahram H. Ghushchyan ◽  
Julia F. Slejko ◽  
Vasily Belozeroff ◽  
Denise R. Globe ◽  
...  

Author(s):  
Ram C. Neupane ◽  
Jason Turner

Asthma is a common chronic disease in the United States, with increasing prevalence. Many patients do not realize therapeutic goals because of poor disease management. The purpose of this study is to examine the costs of the commonly used drugs used to treat asthma. We examined the contribution of individual, government and private agencies for medication payment. We next compared the prescription cost to the cost of emergency room visits. The data are taken from the Medical Expenditure Panel Survey. SAS Enterprise Guide was used for preprocessing and data visualization. It was found that prednisone is the cheapest drug and the drug, albuterol, is the most common, even if it is more expensive. The contribution of the government is higher than the amount paid by individuals and other agencies. We examined data from the National Inpatient Sample to investigate trends in asthma as well.


Sign in / Sign up

Export Citation Format

Share Document